瑞卢,埃达拉和托弗森在ALS治疗中的安全性比较分析:来自FAERS数据库的见解
Shuang Guan1, Sicun Wang1, Yinli Shi1
1Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Frontiers in pharmacology
|November 28, 2025
概括
这项研究比较了Riluzole,Edaravone和Tofersen在治疗肌缩侧硬化症 (ALS) 的不良事件. 利卢和埃达拉显示出明显的副作用,而这三种药物都有血栓形成的风险,突出了个性化治疗的需要.
科学领域:
- 药物监督和神经退行性疾病
- 药物安全性和有效性分析
- 计算生物学和生物信息学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 利卢,埃达拉和托弗森是对ALS的关键治疗方法.
- 不同的安全性概况需要对临床决策进行比较分析.
研究的目的:
- 进行药监测分析,比较ALS治疗中Riluzole,Edaravone和Tofersen的不良事件 (AE) 信号.
- 阐明这三种ALS治疗方法的独特安全性.
- 确定与严重不良反应相关的潜在药物标,包括血栓形成.
主要方法:
- 利用FDA不良事件报告系统数据 (2004年第一季度 - 2024年第二季度) 来分析AE的不成比例性.
- 在蛋白质-蛋白质相互作用网络上应用随机步行与重启 (RWR) 算法,以识别药物向基因.
- 进行了分子对接和转录组分析,以评估药物向相互作用.
主要成果:
- 分析了Riluzole的2106个AE报告,Edaravone的2466个和Tofersen的136个.
- 里卢与腹部不适有关,口服下沉,肝酶增加;埃达拉与跌倒,步态障碍,失言症有关;托弗森与头痛有关,脊髓液红细胞计数呈阳性.
- 血栓形成被确定为共同严重的AE;RWR将F10和MMP9确定为相关的标,对候选药物和F10具有有利的结合.
结论:
- 了解Riluzole,Edaravone和Tofersen的独特AE概况对于个性化的ALS管理至关重要.
- 研究结果提供了对优化ALS患者治疗策略的见解.
- 建议进行进一步的前性研究,以验证发现并探索AE机制.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
167
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
167